| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V116955 | ADC Control Human IgG1-sulfo-SPDB-DM4 | ADC Control Human IgG1-sulfo-SPDB-DM4 is an antibody-drug conjugate (ADC) that inhibits microtubule polymerization. | |
|
V76158 | Izeltabart (IMGC-936) | 2642078-60-0 | Izeltabart (IMGC-936) is a Maytansinoid-based ADC targeting ADAM9. |
|
V114499 | Mirzotamab clezutoclax | 2229859-12-3 | Mirzotamab clezutoclax (ABBV-155) is a first-in-class antibody-drug conjugate (ADC) consisting of three components: an anti-B7-H3 monoclonal antibody and a BCL2L1 (BCL-XL) inhibitor, clezutoclaxum. |
|
V142520 | PF-08046054 | PF-08046054 is an antibody-drug conjugate (ADC) targeting PD-L1, which is composed of an anti-PD-L1 antibody conjugated with VcMMAE. | |
|
V144495 | Sacituzumab tirumotecan | 2768350-77-0 | Sacituzumab tirumotecan is an antibody-drug conjugate and a topoisomerase I inhibitor payload delivery agent targeting TROP2. Its TROP2 EC50 is 2.787 ng/ml, TROP2 Ka is 0.3083 nM, and topoisomerase I IC50 is 0.7 μmol/L. |
|
V144978 | Sirtratumab vedotin | 1824663-83-3 | Sirtratumab vedotin is an antibody-drug conjugate (ADC) composed of a SLITRK6-specific human γ2 antibody (Igγ2) conjugated to a small microtubule disruptor, monomethylaurestatin E (MMAE), via a protease-cleavable linker. |
|
V146854 | Vandortuzumab vedotin | 1471985-92-8 | Vandortuzumab vedotin is an antibody-drug conjugate (ADC) that targets STEAP1. |